CRDF
Cardiff Oncology Inc
Halal Rating :
Last Price
$3.44
Last updated:
Market Cap
-
7D Change
-1.01%
1 Year Change
125.99%
Company Overview
Industries
Exchange
Next Earnings Date
Cardiff Oncology is a clinical-stage biotechnology company focused on developing treatments for cancer patients. The company's primary focus is on developing onvansertib, a selective Polo-like Kinase 1 (PLK1) inhibitor, for various cancer indications, particularly targeting KRAS-mutated metastatic colorectal cancer, pancreatic cancer, and other solid tumors.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $165000.0 | $12.77m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $163000.0 | $12.71m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $205000.0 | $11.14m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Cardiff Oncology Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.